5'-C-Ethyl-tetrazolyl-N(6)-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists.

A series of N(6)-substituted-5'-C-(2-ethyl-2H-tetrazol-5-yl)-adenosine and 2-chloro-adenosine derivatives was synthesized as novel, highly potent dual acting hA1AR agonists and hA3AR antagonists, potentially useful in the treatment of glaucoma and other diseases. The best affinity and selectivity profiles were achieved by N(6)-substitution with a 2-fluoro-4-chloro-phenyl- or a methyl- group. Through an in silico receptor-driven approach, the molecular bases of the hA1- and hA3AR recognition and activation of this series of 5'-C-ethyl-tetrazolyl derivatives were explained.

[1]  D. Gladman,et al.  Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. , 2008, The Journal of rheumatology.

[2]  A. Usiello,et al.  The A1 adenosine receptor as a new player in microglia physiology , 2014, Glia.

[3]  Xunda Luo,et al.  Adenosine, adenosine receptors and glaucoma: an updated overview. , 2013, Biochimica et biophysica acta.

[4]  Kenneth A Jacobson,et al.  Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. , 2006, Bioorganic & medicinal chemistry letters.

[5]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[6]  Riccardo Petrelli,et al.  Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. , 2005, Journal of medicinal chemistry.

[7]  Sang Kook Lee,et al.  Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists. , 2009, Bioorganic & medicinal chemistry.

[8]  K. Jacobson,et al.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. , 2009, Handbook of experimental pharmacology.

[9]  N. Mercuri,et al.  Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice , 2014, Experimental Neurology.

[10]  K. Klotz,et al.  [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. , 2007, European journal of pharmacology.

[11]  Richard J. Hall,et al.  Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.

[12]  Carl R. Johnson,et al.  Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. , 2002, Journal of medicinal chemistry.

[13]  M. Loza,et al.  Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. , 2004, Journal of medicinal chemistry.

[14]  K. Jacobson,et al.  Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands. , 2012, Journal of medicinal chemistry.

[15]  K. Jacobson,et al.  Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. , 2010, Experimental eye research.

[16]  Matteo Floris,et al.  Adenosiland: walking through adenosine receptors landscape. , 2012, European journal of medicinal chemistry.

[17]  J. Fozard,et al.  A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential. , 2005, Bioorganic & medicinal chemistry letters.

[18]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[19]  Kenneth A. Jacobson,et al.  Structural Determinants of A3 Adenosine Receptor Activation: Nucleoside Ligands at the Agonist/Antagonist Boundary , 2002 .

[20]  D. Wilson,et al.  Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor , 2007, European journal of pharmacology.

[21]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[22]  Steven M. Moss,et al.  In Vivo Phenotypic Screening for Treating Chronic Neuropathic Pain: Modification of C2-Arylethynyl Group of Conformationally Constrained A3 Adenosine Receptor Agonists , 2014, Journal of medicinal chemistry.

[23]  P. Fishman,et al.  Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. , 2005, The Journal of rheumatology.

[24]  C. Martini,et al.  2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.

[25]  Peter G Nell,et al.  The adenosine A1 receptor and its ligands. , 2009, Progress in medicinal chemistry.

[26]  Steven M. Moss,et al.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. , 2012, Journal of medicinal chemistry.

[27]  K. Klotz,et al.  Adenosine Receptor with Antinociceptive Effects in Mice , 2009 .

[28]  K. Klotz,et al.  5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. , 2008, Bioorganic & medicinal chemistry.

[29]  M. Jacobson,et al.  References Subscriptions Permissions Email Alerts A Class I MHC-Restricted Recall Response to a Viral Peptide Is Highly Polyclonal Despite Stringent CDR3 Selection: Implications for Establishing Memory T Cell Repertoires in ''Real-World' ' Conditions , 2013 .

[30]  K. Jacobson,et al.  Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element. , 2011, ACS medicinal chemistry letters.

[31]  R. Petrelli,et al.  5'-Chloro-5'-deoxy-(±)-ENBA, a Potent and Selective Adenosine A1 Receptor Agonist, Alleviates Neuropathic Pain in Mice Through Functional Glial and Microglial Changes without Affecting Motor or Cardiovascular Functions , 2012, Molecules.

[32]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[33]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[34]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.